Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

IQVIA Holdings (0JDM) Share Price & Analysis

0 Followers

0JDM Stock Chart & Stats

$265.97-$4.15(-1.54%)
At close: 4:30 PM GMT
$240$260$280Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$263.83 - $274.53
52-Week Range
$150.00 - $287.00
Previous Close
$270.12
Volume
N/A
Average Volume (3M)
404
Market Cap
$43.69B
Enterprise Value
$58.92B
Total Cash (Recent Filing)
$2.42B
Total Debt (Recent Filing)
$16.31B
Price to Earnings (P/E)
31.9
Beta
0.97
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
3.58
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Steady Growth And Profitability

IQVIA has expanded revenue while sustaining healthy operating and net margins, indicating a resilient service model and effective cost control. This combination supports recurring investment in technology and delivery capabilities, giving the company a durable base for continued growth across the product lifecycle.

Clinical Demand And Bookings

Consistent bookings growth provides forward visibility for the clinical development business and validates customer demand for outsourced research services. Rising win rates, broad-based full-service demand, and a 1.2 book-to-bill can support revenue conversion and strengthen IQVIA’s market position over coming quarters.

AI And Technology Differentiation

Broad AI deployment can deepen IQVIA’s differentiation by improving clinical execution, shortening customer timelines, and enabling new technology-based services. Integration with proprietary healthcare data and established life-sciences relationships may increase customer value, support adoption, and create additional recurring revenue opportunities.

Bears Say

Elevated Leverage

High leverage reduces financial flexibility and leaves earnings and cash flow more exposed to refinancing conditions and interest costs. Although IQVIA generates substantial cash, debt service and maturity management can constrain acquisitions, technology investment, and the company’s ability to absorb weaker demand.

Inactive-Trial Backlog Reduction

The backlog reduction indicates that a meaningful portion of previously recorded clinical work is unlikely to resume soon, reducing the quality of headline backlog visibility. Management said it does not affect guidance or near-term revenue, but it highlights the need for disciplined backlog conversion and customer project monitoring.

Growth And Margin Pressure

Slower historical growth and a lower recent gross margin suggest that reported expansion may remain sensitive to business mix and cost pressures. Pass-through activity can dilute margins even when operations improve, making sustained profitability dependent on continued productivity gains and favorable service composition.

IQVIA Holdings News

0JDM FAQ

What was IQVIA Holdings’s price range in the past 12 months?
IQVIA Holdings lowest share price was $150.00 and its highest was $287.00 in the past 12 months.
What is IQVIA Holdings’s market cap?
IQVIA Holdings’s market cap is $43.69B.
When is IQVIA Holdings’s upcoming earnings report date?
IQVIA Holdings’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 88 days.
How were IQVIA Holdings’s earnings last quarter?
IQVIA Holdings released its earnings results on Oct 27, 2026. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.259 by $0.081.
Is IQVIA Holdings overvalued?
According to Wall Street analysts IQVIA Holdings’s price is currently Undervalued.
Does IQVIA Holdings pay dividends?
IQVIA Holdings pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on IQVIA Holdings dividends here
What is IQVIA Holdings’s EPS estimate?
IQVIA Holdings’s EPS estimate is 3.58.
How many shares outstanding does IQVIA Holdings have?
IQVIA Holdings has 164,800,000 shares outstanding.
What happened to IQVIA Holdings’s price movement after its last earnings report?
IQVIA Holdings reported an EPS of $3.34 in its last earnings report, beating expectations of $3.259. Following the earnings report the stock price went down -0.609%.
Which hedge fund is a major shareholder of IQVIA Holdings?
Hedge funds hold IQVIA Holdings shares: the largest hedge-fund position in IQVIA Holdings is 168,369,507 shares, and hedge funds increased their holdings by 657.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology